"Novo Nordisk to slash prices of Wegovy, Ozempic, Rybelsus by up to 50% from 2027. Competition intensifies with Eli Lilly's Mounjaro, Zepbound, and emergin
Title: Novo Nordisk Announces Price Reductions for Wegovy, Ozempic, and Rybelsus Starting 2027
Summary:
- Danish pharmaceutical company Novo Nordisk plans to decrease prices for weight-loss medications Wegovy, Ozempic, and Rybelsus by up to 50% from January 2027.
- The decision follows increasing competition among drug manufacturers in the market for weight-loss treatments.
**Competitive Landscape**
- Novo Nordisk faces competition from Eli Lilly, which offers Mounjaro and Zepbound, injectable weight-loss medications.
- Other GLP-1 treatment providers are also entering the market.
- Wegovy, Ozempic, and Rybelsus are currently available at discounted prices on Trumprx.gov, an online platform launched by the Trump administration.
**Current Market Prices**
- Current monthly price for Wegovy: Not specified
- Proposed monthly price for Wegovy starting 2027: $675 (50% reduction)
- Current monthly price for Ozempic: Not specified
- Proposed monthly price for Ozempic starting 2027: $675 (35% reduction)
- Rybelsus, a pill for type 2 diabetes also used for weight loss, will be priced the same as Wegovy and Ozempic.
**Novo Nordisk's Rationale**
- The company aims to reduce out-of-pocket costs for customers with high-deductible insurance plans.
- Novo Nordisk states that private and public payers, as well as patients, have been advocating for lower list prices.
**Exemptions from Price Cuts**
- The price reductions will not apply to "direct-to-patient" prices, which are discounted rates offered directly to consumers by the manufacturer.
**Previous Pricing Initiatives**
- In November 2021, Novo Nordisk announced a new pricing plan for Wegovy and Ozempic aimed at reducing costs for some customers.
Source: Read Original Article
Post a Comment